NOVEMBER 5, 2008 -- Ellex Medical Lasers Ltd. (Adelaide, Australia) says two optimal wavelengths and high power not previously available in photocoagulators -- 1.5 watts of 561nm yellow and 1 watt of 670nm red -- permits the full treatment range of three-wavelength photocoagulators, displacing the need for green wavelengths. During the American Academy of Ophthalmology (AAO) event starting this weekend (November 8-11, Atlanta, GA), the company will preview a new system, set to debut in 2009, that combines these lasers.
Compared to traditional 514/532nm green, Ellex says the 561nm yellow creates a more gentle retinal burn and results in low scotoma formation. This, in turn, provides for better control over the interaction between laser beam and tissue. The yellow wavelength is not absorbed by xanthophyll, which makes it suitable for treatments in and around the macula. It also produces less scatter, which creates superior transmission through existing opacities, including cataracts. The high power permits iridotomies and laser trabeculoplasties.
The 670nm red wavelength transmits through minor hemorrhages, and it is well absorbed by the retinal pigment epithelium and choroidal melanocytes. The results are gentle, deep retinal tissue penetration and effective treatment of choroidal vessels, Ellex says.
Ellex calls the new system, which it plans to release in 2009, Integre Pro. "The concept is a first for the industry, enabling physicians to take advantage of the full spectrum of photocoagulation treatments traditionally required by three separate laser wavelengths," says Ellex CEO Simon Luscombe.
Integre Pro promises complete, cable-free integration of the laser with the slit lamp, a second port for easy adaptation of a second delivery device, and a proprietary single-pump dual cavity design that allows for instant switching between wavelengths. Ellex's Integre family of integrated photocoagulators also includes the Integre (532nm green) and Integre Duo (523nm green/670nm red).
Ellex Medical Lasers Ltd.